Gland Pharma Limited (BOM:543245)
India · Delayed Price · Currency is INR 2,313.30
+6.55 (0.28%)
At close: May 27, 2026
Gland Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 10,273 | 6,985 | 7,725 | 7,810 | 12,117 |
Depreciation & Amortization | 4,237 | 3,779 | 3,446 | 1,467 | 1,103 |
Loss (Gain) From Sale of Assets | 3.84 | 0.32 | -2.49 | 0.81 | 1.78 |
Asset Writedown & Restructuring Costs | - | 18.24 | - | 63.32 | - |
Loss (Gain) From Sale of Investments | -33.06 | -12.27 | -3.48 | -28.48 | -44.89 |
Stock-Based Compensation | 454.68 | - | - | - | 46.21 |
Provision & Write-off of Bad Debts | 5.45 | 46.23 | 214.21 | 22.04 | 41.27 |
Other Operating Activities | -2,082 | -1,609 | -878.54 | -1,516 | -1,426 |
Change in Accounts Receivable | -2,786 | 422.88 | -3,250 | 1,440 | -4,196 |
Change in Inventory | 187.23 | -199.18 | 6,661 | -7,596 | 895.01 |
Change in Accounts Payable | -548.83 | 269.03 | -3,789 | 1,210 | 659.19 |
Change in Other Net Operating Assets | 602.83 | -553.36 | -154.51 | 767.19 | -1,289 |
Operating Cash Flow | 10,314 | 9,147 | 9,968 | 3,640 | 7,908 |
Operating Cash Flow Growth | 12.75% | -8.23% | 173.87% | -53.97% | 30.72% |
Capital Expenditures | -4,908 | -3,845 | -3,899 | -2,209 | -5,113 |
Sale of Property, Plant & Equipment | 5.89 | 3.38 | 7.67 | 1.4 | 3.99 |
Cash Acquisitions | - | - | -10,218 | - | - |
Sale (Purchase) of Intangibles | -36.66 | -96.24 | -83.26 | -21.9 | -107.92 |
Investment in Securities | 3,993 | 19,421 | -4,747 | 12,706 | -6,117 |
Other Investing Activities | 2,323 | 1,565 | 1,371 | 1,606 | 1,308 |
Investing Cash Flow | 1,377 | 17,047 | -17,569 | 12,082 | -10,026 |
Long-Term Debt Issued | 225.23 | 52.83 | 210.28 | - | - |
Long-Term Debt Repaid | -1,106 | -811.64 | -7,954 | -2.9 | -2.52 |
Total Debt Repaid | -1,106 | -811.64 | -7,954 | -2.9 | -2.52 |
Net Debt Issued (Repaid) | -880.62 | -758.81 | -7,743 | -2.9 | -2.52 |
Issuance of Common Stock | - | 24.88 | 5.26 | 214.96 | 385.52 |
Common Dividends Paid | -2,966 | -3,295 | - | - | - |
Other Financing Activities | -323.58 | -305.95 | -256.11 | -62.87 | -34.02 |
Financing Cash Flow | -4,170 | -4,335 | -7,994 | 149.19 | 348.98 |
Foreign Exchange Rate Adjustments | 507.53 | 131.31 | 77.23 | 30 | 33.11 |
Net Cash Flow | 8,029 | 21,991 | -15,518 | 15,901 | -1,736 |
Free Cash Flow | 5,406 | 5,302 | 6,069 | 1,430 | 2,794 |
Free Cash Flow Growth | 1.97% | -12.63% | 324.27% | -48.81% | -25.71% |
Free Cash Flow Margin | 8.41% | 9.44% | 10.71% | 3.95% | 6.35% |
Free Cash Flow Per Share | 32.77 | 32.18 | 36.84 | 8.69 | 16.98 |
Cash Interest Paid | 323.58 | 305.95 | 256.11 | 62.87 | 34.02 |
Cash Income Tax Paid | 4,555 | 3,538 | 3,061 | 3,109 | 4,065 |
Levered Free Cash Flow | 5,041 | 5,719 | 4,104 | 875.11 | 493.54 |
Unlevered Free Cash Flow | 5,249 | 5,953 | 4,240 | 914.4 | 514.8 |
Change in Working Capital | -2,545 | -60.63 | -531.99 | -4,179 | -3,930 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.